Skip to main content
SpringerLink
Log in

Management of Special Issues

  • Chapter
Peritoneal Surface Malignancies

Abstract

Past three decades, management of peritoneal metastases of appendiceal mucinous neoplasms, colorectal cancer and malign mesothelioma has dramatically changed with cytoreductive surgery and heated intraperitoneal intraoperative chemotherapy applications. This comprehensive management is also promising approach as a gold standard of care for peritoneal metastases of gastric and ovarian cancer. In this chapter, we will summarize the diseases with peritoneal metastases and management with combined treatment approaches and prognosis of these diseases with peritoneal metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Battifora H, McCaughey WTE. Tumors of the serosal membranes. Washington DC: Armed Forces Institute of Pathology; 1994.

    Google Scholar 

  2. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12(3):605–21.

    PubMed  Google Scholar 

  3. Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, Pass HI, Rizzo P, Carbone M. Human mesothelial cell are usually susceptible to simian-virus 40-mediated transformationand asbestos cocarcinogenesis. Proc Natl Acad Sci U S A. 2000;97(18):10214–9219.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Manfredi JJ, Dong J, Liu WJ, Resnick-Silverman L, Qiao R, Chahinian P, Saric M, Gibbs AR, Phillips JI, Murray J, Axten CW, Nolan RP, Aaronson SA. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005;65(7):2602–9.

    CAS  PubMed  Google Scholar 

  5. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357(9254):444–5.

    CAS  PubMed  Google Scholar 

  6. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60(5):395–9.

    PubMed  Google Scholar 

  7. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin Level. N Engl J Med. 2005;353(15):1564–73.

    CAS  PubMed  Google Scholar 

  8. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612–6.

    CAS  PubMed  Google Scholar 

  9. Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increase its potential as a useful serum tumour marker for mesothelioma. Clin Cancer Res. 2008;14(5):1431–7.

    CAS  PubMed  Google Scholar 

  10. Roboz J, Greaves J, Silides D, Chahinian AP, Holland JF. Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. Cancer Res. 1985;45(4):1850–4.

    CAS  PubMed  Google Scholar 

  11. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Tanimura H, Tsubota YT. Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma. Hepatogastroenterology. 2004;51(58):1073–83.

    PubMed  Google Scholar 

  12. Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14(8):2300–8.

    PubMed  Google Scholar 

  13. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women. A study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol. 2005;123:724–37.

    PubMed  Google Scholar 

  14. Kannerstein M, Churg J. Peritoneal mesothelioma. Human Pathol. 1977;8(1):83–94.

    CAS  Google Scholar 

  15. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166(3):913–21.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18(1):105–10.

    CAS  PubMed  Google Scholar 

  17. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int. 2005;55(2):83–6.

    CAS  PubMed  Google Scholar 

  18. Ordónez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesothelioma and serous carcinomas: a comparative study. Mod Pathol. 2006;19(1):34–48.

    PubMed  Google Scholar 

  19. Oates J, Edwards C. HBME-1, MOK-31, WT1 and calretinin: as an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36(4):341–7.

    CAS  PubMed  Google Scholar 

  20. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16(3):192–7.

    PubMed  Google Scholar 

  21. Amin KM, Litzky LA, Smythe WR, et al. Wilms’ tumour 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol. 1995;146(2):344–56.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelial mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27(8):1031–51.

    PubMed  Google Scholar 

  23. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on the study of natural history. Am J Med. 1980;68(3):356–62.

    CAS  PubMed  Google Scholar 

  24. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.

    PubMed  Google Scholar 

  25. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH, editor. Peritoneal carinomatosis: principles of management. Norwell: Kluwer Academic Publishers; 1996. p. 79–100.

    Google Scholar 

  26. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17(1):45–53.

    PubMed  Google Scholar 

  27. Pfannenberg C, Königsrainer I, Aschoff P, Oksüz MO, Zieker D, Beckert S, Symons S, Nieselt K, Glatzle J, Weyhern CV, Brücher BL, Claussen CD, Königsrainer A. 18F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2009;16(5):1295–303.

    PubMed  Google Scholar 

  28. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003;44(9):1407–12.

    PubMed  Google Scholar 

  29. Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of exploratory laparotomy to evaluate optimal candidate for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23(1):187–90.

    PubMed  Google Scholar 

  30. Tanaka T, Kawai Y, Kanai M, Taki Y, Nakamoto Y, Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg. 2002;184(5):433–6.

    PubMed  Google Scholar 

  31. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermiac chemotherapy; results of a prospective study. Ann Surg Oncol. 2006;13(3):405–12.

    CAS  PubMed  Google Scholar 

  32. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91(6):739–46.

    CAS  PubMed  Google Scholar 

  33. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Peritoneal Surface Oncology Group. A novel tumour-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117(9):1855–63.

    PubMed  Google Scholar 

  34. Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin N Am. 2005;19(6):1117–36.

    Google Scholar 

  35. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP. Activity of chemotherapy and immuno therapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38(2):112–21.

    Google Scholar 

  36. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.

    CAS  PubMed  Google Scholar 

  37. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.

    PubMed  Google Scholar 

  38. Langer CJ, Rosenblum N, Hogan M, Nash S, Bagchi P, LaCreta FP, Catalano R, Comis RL, O’Dwyer PJ. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol. 1993;32(3):204–8.

    CAS  PubMed  Google Scholar 

  39. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.

    CAS  PubMed  Google Scholar 

  40. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7.

    CAS  PubMed  Google Scholar 

  41. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229–37.

    PubMed  Google Scholar 

  42. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67(10):999–1003.

    CAS  PubMed  Google Scholar 

  43. Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH. Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori. 2005;91(5):394–400.

    PubMed  Google Scholar 

  44. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130(11):1654–61.

    PubMed  Google Scholar 

  45. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243(2):212–22.

    PubMed Central  PubMed  Google Scholar 

  46. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE –I. Multicentric prospective study. Cancer. 2000;88(2):358–863.

    CAS  PubMed  Google Scholar 

  47. Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MB, Cellerino R, Piga A. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil based regimens. Am J Clin Oncol. 2002;25(2):140–8.

    PubMed  Google Scholar 

  48. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.

    PubMed  Google Scholar 

  49. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.

    CAS  PubMed  Google Scholar 

  50. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicenter randomised trial. Lancet. 2000;355(9209):1041–7.

    CAS  PubMed  Google Scholar 

  51. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.

    CAS  PubMed  Google Scholar 

  52. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697–705.

    CAS  PubMed  Google Scholar 

  53. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    CAS  PubMed  Google Scholar 

  54. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.

    CAS  PubMed  Google Scholar 

  55. Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol. 2006;17(8):1249–54.

    CAS  PubMed  Google Scholar 

  56. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.

    CAS  PubMed  Google Scholar 

  57. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.

    CAS  PubMed  Google Scholar 

  58. Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L, Silva RR, Falcone A, D’Emidio S, Fedeli SL. Mucionous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first line oxaliplatin and/or irinotecan based chemotherapy. Br J Cancer. 2009;100(6):881–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22(16):3284–92.

    CAS  Google Scholar 

  60. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65–71.

    PubMed  Google Scholar 

  61. da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–86.

    PubMed  Google Scholar 

  62. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245(4):597–603.

    PubMed Central  PubMed  Google Scholar 

  63. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.

    PubMed  Google Scholar 

  64. Shen P, Thai K, Stewart JH, Howerton R, Loggie BW, Russell GB, Levine EA. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol. 2008;15(12):3422–32.

    PubMed  Google Scholar 

  65. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(5):681–5.

    Google Scholar 

  66. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh 3rd HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62.

    PubMed  Google Scholar 

  67. Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, Rat P, Gilly F. Association Française de Chirurgie. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251(5):896–901.

    PubMed  Google Scholar 

  68. Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2012;38(6):509–15.

    CAS  Google Scholar 

  69. Cashin PH, Graf W, Nygren P, Mahteme H. Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2012;23(3):647–52.

    CAS  Google Scholar 

  70. Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013:978394.

    Google Scholar 

  71. Robella M, Vaira M, Marsanic P, Mellano A, Cinquegrana A, Sottile A, De Simone M. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients. Minerva Chir. 2013;68(6):551–8.

    CAS  PubMed  Google Scholar 

  72. Gomez da Silva R, Cabana J, Sugarbaker PH. Limited survival in the treatment of carcinomatosis from rectal cancer. Dis Colon Rectum. 2005;48:2258–63.

    Google Scholar 

  73. Sugarbaker PH. Peritoneal Surface Oncology: review of a personal experience with colorectal and appendiceal malignancy. Tech Coloproctol. 2005;9:95–103.

    CAS  PubMed  Google Scholar 

  74. Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spilioitis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol. 2014;23.

    Google Scholar 

  75. Fann JI, Vierra M, Fisher D, Oberhelman Jr HA, Cobb L. Pseudomyxoma peritonei. Surg Gynecol Obstet. 1993;177(5):441–7.

    CAS  PubMed  Google Scholar 

  76. Mukherjee A, Parvaiz A, Cecil TD, Moran BJ. Pseudomyxoma peritonei usually originates from appendix: a review of the evidence. Eur J Gynaecol Oncol. 2004;25(4):411–4.

    CAS  PubMed  Google Scholar 

  77. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, Dalton RR, Ettinghausen SE, Jacquet P, Jelinek J, Koslowe P, Kurman RJ, Shmookler B, Stephens AD, Steves MA, Stuart OA, White S, Zahn CM, Zoetmulder FA. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233–80.

    CAS  PubMed  Google Scholar 

  78. Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol. 2004;86(1):10–5.

    PubMed  Google Scholar 

  79. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19(12):1390–408.

    CAS  PubMed  Google Scholar 

  80. Kamal SM, Bakar MA, Ali MY, Ahad MA. Pseudomyxoma peritonei: a review. Faridpur Med Coll J. 2012;7(2):88–92.

    Google Scholar 

  81. Sugarbaker PH, Jablonski KA. Prognostic feature of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.

    CAS  PubMed Central  PubMed  Google Scholar 

  82. Costa MJ. Pseudomyxoma peritonei. Histologic predictors of patient survival. Arch Pathol Lab Med. 1994;118(12):1215–9.

    CAS  PubMed  Google Scholar 

  83. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, van Heerden JA. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219(2):112–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  84. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241(2):300–8.

    PubMed Central  PubMed  Google Scholar 

  85. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089–103.

    PubMed  Google Scholar 

  86. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum. 1987;30(10):772–9.

    CAS  PubMed  Google Scholar 

  87. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–31.

    CAS  PubMed  Google Scholar 

  88. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240(2):278–85.

    PubMed Central  PubMed  Google Scholar 

  89. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93(10):1270–6.

    CAS  PubMed  Google Scholar 

  90. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–9.

    PubMed Central  PubMed  Google Scholar 

  91. Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15(2):526–34.

    PubMed  Google Scholar 

  92. Elias D, Honoré C, Ciuchendéa R, Billard V, Raynard B, Lo Dico R, Dromain C, Duvillard P, Goéré D. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95(9):1164–71.

    CAS  PubMed  Google Scholar 

  93. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.

    PubMed  Google Scholar 

  94. Esquivel J, Sanchez Garcia S, Hicken W, Seibel J, Shkitka K, Trout R. Evaluation of a New Staging Classification and a Peritoneal Surface Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination. J Surg Oncol. 2014;110(6):656–60.

    PubMed  Google Scholar 

  95. Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M. Pathology and prognosis of gastric carcinoma. Findings in 10000 patients who underwent primary gastrectomy. Cancer. 1992;70(5):1030–7.

    CAS  PubMed  Google Scholar 

  96. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1–11.

    CAS  PubMed  Google Scholar 

  97. Ikeguchi M, Oka A, Tsujitani S, Maeta M, Kaibara N. Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer. Anticancer Res. 1994;14(5B):2131–4.

    CAS  PubMed  Google Scholar 

  98. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ. Adjuvant therapy after curative resection for gastric cancer: metaanalysis of randomized trials. J Clin Oncol. 1993;11:1441–7.

    CAS  PubMed  Google Scholar 

  99. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988;208(1):36–41.

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg. 1991;15(4):530–5.

    CAS  PubMed  Google Scholar 

  101. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Ohkubo H. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer. 1997;79(5):884–9.

    CAS  PubMed  Google Scholar 

  102. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, François Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139(1):20–6.

    CAS  PubMed  Google Scholar 

  103. Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004;8(4):454–63.

    PubMed  Google Scholar 

  104. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005;92(3):370–5.

    CAS  PubMed  Google Scholar 

  105. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.

    PubMed  Google Scholar 

  106. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.

    PubMed Central  PubMed  Google Scholar 

  107. Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(5):1448–55.

    PubMed Central  PubMed  Google Scholar 

  108. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    CAS  PubMed  Google Scholar 

  109. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am. 2003;12(3):635–48.

    PubMed  Google Scholar 

  110. Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, Takao N, Yonemura Y. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–52.

    PubMed  Google Scholar 

  111. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12–26.

    CAS  PubMed  Google Scholar 

  112. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005;15(1):3–11.

    PubMed  Google Scholar 

  113. Barda G, Menczer J, Chetrit A, Lubin F, Beck D, Piura B, Glezerman M, Modan B, Sadetzki S, National Israel Ovarian Cancer Group. Comparison between primary peritoneal and epithelial ovarian carcinoma. A population based study. Am J Obstet Gynecol. 2004;190(4):1039–45.

    PubMed  Google Scholar 

  114. Tuma RS. Origin of ovarian cancer may have implications for screening. J Natl Cancer Inst. 2010;102(1):11–3.

    PubMed  Google Scholar 

  115. American Joint Committee on Cancer. Ovary and primary peritoneal carcinoma. In: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 419–28.

    Google Scholar 

  116. FIGO. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynecol Obstet. 2009;105:3–4.

    Google Scholar 

  117. Lee EJ, Kim SH, Kim YH, Lee HJ. Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from Stage I carcinoma? Acta Radiol. 2011;52(4):458–62.

    PubMed  Google Scholar 

  118. Chandrashekhara SH, Thulkar S, Srivastava DN, Kumar L, Hariprasad R, Kumar S, Sharma MC. Preoperative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer. Br J Radiol. 2011;84(997):38–43.

    CAS  PubMed Central  PubMed  Google Scholar 

  119. Kyriazi S, Collins DJ, Morgan VA, Giles SL, deSouza NM. Diffusion weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics. 2010;30(5):1269–85.

    PubMed  Google Scholar 

  120. Sala E, Kataoka M, Pandit-Taskar N. Recurrent ovarian cancer: use of contrast enhanced CT and PET-CT to accurately localize tumor recurrence and to predict patients survival. Radiology. 2010;257(1):125–34.

    PubMed Central  PubMed  Google Scholar 

  121. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D’Angelica MI, Barakat RR, Chi DS. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083–90.

    PubMed  Google Scholar 

  122. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7.

    CAS  PubMed  Google Scholar 

  123. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006;(1):CD005340.

    Google Scholar 

  124. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.

    PubMed  Google Scholar 

  125. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: meta analysis. Gynecol Oncol. 2009;112(1):265–74.

    PubMed  Google Scholar 

  126. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, Bruno F, De Riu L, Airoldi M, Pedani F. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004;28(10):1040–5.

    PubMed  Google Scholar 

  127. Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, Kim SJ, Lee JM. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004;94(2):325–32.

    CAS  PubMed  Google Scholar 

  128. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    CAS  PubMed  Google Scholar 

  129. Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, Baratti D, Mariani L, Laterza B, Deraco M. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced /recurrent ovarian cancer patients: the experience of national cancer institute of Milan. Eur J Surg Oncol-J Eur Soc Surg Oncol-Br Assoc Surg Oncol. 2006;32:671–5.

    CAS  Google Scholar 

  130. Rufián S, Muñoz-Casares FC, Briceño J, Díaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntané J, Pera C. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006;15(94):316–24.

    Google Scholar 

  131. Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, Gilly FN. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31(9):1813–20.

    PubMed  Google Scholar 

  132. Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Ahn WS, Namkoong SE. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106(1):193–200.

    CAS  PubMed  Google Scholar 

  133. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113(2):315–25.

    PubMed  Google Scholar 

  134. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer – 12 – year single center experience. Eur J Surg Oncol- J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2009;35(11):1186–91.

    CAS  Google Scholar 

  135. Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–20.

    PubMed  Google Scholar 

  136. Tentes AA, Kakolyris S, Kyziridis D, Karamveri C. Cytoreductive surgery combined with hyperthermic intraperitoneal intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol. 2012;2012:358341.

    PubMed Central  PubMed  Google Scholar 

  137. Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19(13):4052–8.

    CAS  PubMed  Google Scholar 

  138. Cascales-Campos PA, Gil J, Gil E, Felicangeli E, Gonzales-Gil A, Parrilla JJ, Parrilla P. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease free survival in patients with Stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014;21(7):2383–9.

    PubMed  Google Scholar 

  139. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637–45.

    PubMed  Google Scholar 

  140. Donegan WL. Cancer and pregnancy. CA Cancer J Clin. 1983;33:194–214.

    CAS  PubMed  Google Scholar 

  141. Donnenfeld AE, Roberts NS, Losure TA, Mellen AW. Perforated adenocarcinoma of the appendix during pregnancy. Am J Obstet Gynecol. 1986;154(3):637–8.

    CAS  PubMed  Google Scholar 

  142. Sebire NJ, Osborn M, Darzi A, Farthing A, Goldin RD. Appendiceal adenocarcinoma with ovarian metastases in the third trimester of pregnancy. J R Soc Med. 2000;93(4):192–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  143. Gallo JL, Martínez-Ossa R, Ferrer G, Cámara M. Mucinous appendiceal cystadenocarcinoma and pregnancy. Am J Perinatal. 2001;18(3):155–7.

    CAS  Google Scholar 

  144. Zeteroğlu S, Kotan C, Ozen S, Goktolga U. Mucinous appendicular cystadenocarcinoma during pregnancy. J Reprod Med. 2003;48(10):831–3.

    PubMed  Google Scholar 

  145. Morgan DR, Fernandez CO, DeSarno C, Mann Jr WJ. Adenocarcinoma of appendix in pregnancy: a case report. J Reprod Med. 2004;49(9):753–5.

    PubMed  Google Scholar 

  146. Haase E, Yoo D, Sugarbaker PH. Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy. World J Surg Oncol. 2009;7:48.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peritoneal Dissemination Treatment, Istanbul, Istanbul, Turkey

    Emel Canbay

  2. Peritoneal Carcinomatosis Center Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan

    Yutaka Yonemura

Authors
  1. Emel Canbay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Yonemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Canbay, E., Yonemura, Y. (2015). Management of Special Issues. In: Peritoneal Surface Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12937-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12937-2_4

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12936-5

  • Online ISBN: 978-3-319-12937-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation